iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $391,454.72 in Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,228 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

David Hallal also recently made the following trade(s):

• On Thursday, June 5th, David Hallal sold 38,227 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.15, for a total transaction of $388,004.05.

iTeos Therapeutics Stock Down 0.1%

ITOS traded down $0.01 during trading on Friday, reaching $10.17. 1,062,628 shares of the company were exchanged, compared to its average volume of 658,136. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13. The company's 50-day moving average is $7.38 and its two-hundred day moving average is $7.47. The company has a market cap of $389.25 million, a price-to-earnings ratio of -3.23 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Equities analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Leerink Partners restated a "market perform" rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. cut iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. Piper Sandler reissued an "overweight" rating and issued a $12.00 price objective (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, iTeos Therapeutics currently has an average rating of "Hold" and an average price target of $15.86.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of iTeos Therapeutics during the 1st quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics during the fourth quarter valued at $42,000. CWM LLC grew its position in iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after buying an additional 6,936 shares in the last quarter. Paloma Partners Management Co purchased a new position in iTeos Therapeutics during the first quarter worth about $65,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in iTeos Therapeutics in the 1st quarter worth about $67,000. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.